In a patient with advanced cirrhosis (alcoholic, viral hepatitis, or non‑alcoholic steatohepatitis) who develops a rapid increase in serum creatinine to ≥1.5 mg/dL and oliguria without an obvious renal cause, how should hepatorenal syndrome be suspected, diagnosed, and treated?

Hepatorenal Syndrome: Diagnosis and Management

Immediate Diagnostic Confirmation

In a patient with advanced cirrhosis presenting with rapid creatinine rise to ≥1.5 mg/dL and oliguria, hepatorenal syndrome (HRS-AKI) should be diagnosed when all of the following criteria are met: cirrhosis with ascites, AKI defined by creatinine increase ≥0.3 mg/dL within 48 hours or ≥50% from baseline, no improvement after 2 consecutive days of diuretic withdrawal and albumin expansion (1 g/kg, maximum 100 g on day 1), absence of shock, no nephrotoxic drug exposure, and no structural kidney disease (proteinuria <500 mg/day, <50 RBCs/HPF, normal renal ultrasound). 1, 2

Critical Initial Steps (First 48 Hours)

• Immediately stop all diuretics, beta-blockers, NSAIDs, and any nephrotoxic medications upon recognizing AKI (creatinine increase ≥0.3 mg/dL within 48 hours). 1

• Perform diagnostic paracentesis within hours to exclude spontaneous bacterial peritonitis (SBP), which precipitates HRS in approximately 30% of cases and requires specific treatment with antibiotics plus albumin. 1, 3

• Administer albumin 1 g/kg (maximum 100 g) on day 1, followed by 20-40 g on day 2 after stopping diuretics to differentiate HRS-AKI from volume-responsive prerenal azotemia; lack of creatinine improvement after 48 hours confirms HRS-AKI. 1, 3

• Obtain blood and urine cultures, chest radiograph, and urinalysis with microscopy to identify infection and exclude structural kidney disease. 1

Staging and Prognostic Assessment

• Stage the AKI immediately: Stage 1 = creatinine increase ≥0.3 mg/dL or 1.5-2× baseline; Stage 2 = 2-3× baseline; Stage 3 = >3× baseline or >4 mg/dL with acute increase ≥0.3 mg/dL. 1

• HRS-AKI is defined as Stage 2 or 3 AKI (creatinine doubling or greater) that persists despite the 48-hour albumin challenge and meets all other HRS criteria. 1, 2

• Baseline creatinine >3 mg/dL, bilirubin >10 mg/dL, and ACLF grade 3 predict poor response to vasoconstrictor therapy. 3, 4, 5

Pharmacologic Treatment Algorithm

First-Line: Terlipressin Plus Albumin

Terlipressin plus albumin achieves HRS reversal in 64-76% of patients and is the most effective pharmacologic therapy. 1, 3, 6

• Start terlipressin 1 mg IV every 4-6 hours (equivalent to 0.85 mg terlipressin acetate) plus albumin 1 g/kg (maximum 100 g) on day 1, then albumin 20-40 g/day. 1, 3, 6

• On day 3-4, if creatinine has not decreased ≥25%, escalate terlipressin to 2 mg IV every 4 hours (maximum 12 mg/day). 1, 3

• Continuous infusion alternative: Terlipressin 2 mg/day by continuous IV infusion reduces adverse events compared to bolus dosing while maintaining equal efficacy. 3, 4

• Continue treatment until creatinine ≤1.5 mg/dL on two consecutive measurements ≥2 hours apart, or for maximum 14 days. 1, 3, 6

• Absolute contraindications: Active coronary, peripheral, or mesenteric ischemia; obtain baseline ECG before initiating therapy. 1, 3

• Common ischemic complications include angina, arrhythmias, digital ischemia, and intestinal ischemia; start at the lowest dose and titrate gradually. 1, 3

• Monitor for respiratory failure, especially in patients with ACLF grade 3 or baseline respiratory compromise; approximately 30% of terlipressin-treated patients in the CONFIRM trial experienced respiratory failure. 3, 6

Second-Line: Norepinephrine Plus Albumin

When terlipressin is unavailable or contraindicated, norepinephrine 0.5-3 mg/hour continuous IV infusion plus albumin is equally effective but requires ICU-level monitoring with central venous access. 1, 3

• Start norepinephrine at 0.5 mg/hour and titrate every 4 hours by 0.5 mg/hour to raise mean arterial pressure (MAP) by 10-15 mmHg. 1, 3

• Central venous access is mandatory; peripheral administration risks tissue necrosis. 3

Third-Line: Midodrine Plus Octreotide Plus Albumin

This regimen achieves HRS reversal in only 28-29% of patients versus 70% with terlipressin and should be reserved for settings where terlipressin and norepinephrine are unavailable. 3, 7

• Midodrine 7.5 mg orally three times daily, titrated to 12.5 mg three times daily, plus octreotide 100 μg subcutaneously three times daily, titrated to 200 μg three times daily, plus albumin 20-40 g/day for up to 20 days. 1, 3

• This regimen can be administered outside the ICU and even at home, unlike norepinephrine. 3

• In patients with known ischemic heart disease, the midodrine-octreotide-albumin combination is the safest vasoconstrictor option because terlipressin is absolutely contraindicated in active coronary ischemia. 3

Critical Monitoring Parameters

• Check serum creatinine every 2-3 days to assess renal response. 1, 3

• Monitor MAP continuously; target increase of 10-15 mmHg above baseline. 1, 3

• Expect heart rate to decrease by approximately 10 beats/minute with terlipressin. 1, 3

• Monitor central venous pressure when available to guide fluid balance and prevent volume overload. 1, 3

• Watch vigilantly for pulmonary edema, especially in patients with underlying cardiac dysfunction or cirrhotic cardiomyopathy; albumin-induced volume overload is a major risk. 1, 3

• Complete response is defined as creatinine ≤1.5 mg/dL on two consecutive measurements; partial response is creatinine decrease ≥25% but still >1.5 mg/dL. 1, 3

• Median time to response is 14 days, shorter in patients with lower baseline creatinine. 3

Albumin Management in Volume-Overloaded Patients

If anasarca develops during treatment, discontinue albumin but continue vasoconstrictors for the full treatment course; vasoconstrictors are the primary therapeutic agents and must not be stopped. 3

• After HRS-AKI confirmation, albumin dosing should be individualized according to volume status rather than continued at a fixed dose; the 2024 AGA guideline emphasizes this departure from older fixed-dose recommendations. 8, 3

• Fixed albumin dosing without volume assessment can precipitate pulmonary edema or provide insufficient therapy. 8, 3

Renal Replacement Therapy

Initiate RRT only as a bridge to liver transplantation in patients unresponsive to vasoconstrictors; RRT should not be used in HRS-AKI patients who are not transplant candidates. 1, 3

• Specific indications for RRT include: refractory electrolyte/acid-base disturbances, refractory volume overload despite albumin discontinuation, symptomatic azotemia, or worsening renal function despite maximum vasoconstrictor therapy. 3

Liver Transplantation

Liver transplantation is the only curative treatment for HRS-AKI; expedited referral is recommended for all type 1 HRS patients. 1, 3, 7

• Treatment with vasoconstrictors before transplantation improves post-transplant outcomes; HRS reverses in approximately 75% of patients after liver transplantation alone. 1, 3

• Combined liver-kidney transplantation should be considered when measured GFR is <30 mL/min or when AKI persists for >4 weeks despite treatment. 1

Prevention Strategies

• Administer albumin 1.5 g/kg at SBP diagnosis, then 1 g/kg on day 3; this reduces HRS incidence from 30% to 10% and mortality from 29% to 10%. 3

• Provide IV albumin 6-8 g per liter of ascitic fluid removed when performing large-volume paracentesis (>5 L) to prevent post-paracentesis circulatory dysfunction. 3

• Norfloxacin 400 mg/day prophylaxis in patients with advanced cirrhosis and low ascitic fluid protein reduces HRS incidence. 3, 7

• Antibiotic prophylaxis for 7 days after gastrointestinal bleeding prevents bacterial infections that precipitate HRS. 3

Common Pitfalls to Avoid

• Do not wait for creatinine to reach 2.5 mg/dL before diagnosing HRS; the old fixed threshold has been abandoned because it delays diagnosis and worsens outcomes. 1, 2

• Do not delay vasoconstrictor therapy; early initiation before progression to higher ACLF grades improves outcomes. 3, 5

• Do not omit albumin from the treatment regimen; albumin provides essential volume expansion and anti-inflammatory effects. 3, 5

• Do not persist with ineffective therapy; if creatinine fails to decrease ≥25% after 3-4 days despite dose escalation, consider alternative vasoconstrictors, RRT, or transplantation. 3

• Do not use TIPS as specific treatment for HRS-AKI; TIPS is more applicable in type 2 HRS (HRS-NAKI) due to more stable clinical condition. 1, 3

• Do not re-initiate terlipressin after an ischemic event, even if symptoms resolve, due to risk of recurrent ischemic complications. 3